21 July 2026
21 July 2026
The new test characterises small neoplastic cell populations and delivers higher sensitivity.
AKG-100 was well tolerated at all dose levels tested, up to a maximum of 850mg.
The companies aim to enable simplified dosing and delivery methods for patients receiving treatment for MPNs.
The technology offers a dual-sided design with a nonporous underside and porous polyethylene structure on other sides.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
